Skip to main content

MicroRNA-144 Silencing Protects Against Atherosclerosis in Male, but Not Female Mice.

Citation
Cheng, J., et al. “Microrna-144 Silencing Protects Against Atherosclerosis In Male, But Not Female Mice.”. Arteriosclerosis, Thrombosis, And Vascular Biology, pp. 412-425.
Center UCSD-UCLA
Author Joan Cheng, Angela Cheng, Bethan L Clifford, Xiaohui Wu, Ulf Hedin, Lars Maegdefessel, Nathalie Pamir, Tamer Sallam, Elizabeth J Tarling, Thomas Q de Aguiar Vallim
Keywords antisense oligonucleotides, atherosclerosis, Cardiovascular disease, cholesterol, microRNA
Abstract

OBJECTIVE: Atherosclerosis is a leading cause of death in developed countries. MicroRNAs act as fine-tuners of gene expression and have been shown to have important roles in the pathophysiology and progression of atherosclerosis. We, and others, previously demonstrated that microRNA-144 (miR-144) functions to post-transcriptionally regulate ABCA1 (ATP binding cassette transporter A1) and plasma HDL (high-density lipoprotein) cholesterol levels. Here, we explore how miR-144 inhibition may protect against atherosclerosis. Approach and Results: We demonstrate that miR-144 silencing reduced atherosclerosis in male, but not female low-density lipoprotein receptor null () mice. MiR-144 antagonism increased circulating HDL cholesterol levels, remodeled the HDL particle, and enhanced reverse cholesterol transport. Notably, the effects on HDL and reverse cholesterol transport were more pronounced in male mice suggesting sex-specific differences may contribute to the effects of silencing miR-144 on atherosclerosis. As a molecular mechanism, we identify the oxysterol metabolizing enzyme CYP7B1 (cytochrome P450 enzyme 7B1) as a miR-144 regulated gene in male, but not female mice. Consistent with miR-144-dependent changes in CYP7B1 activity, we show decreased levels of 27-hydroxycholesterol, a known proatherogenic sterol and the endogenous substrate for CYP7B1 in male, but not female mice.

CONCLUSIONS: Our data demonstrate silencing miR-144 has sex-specific effects and that treatment with antisense oligonucleotides to target miR-144 might result in enhancements in reverse cholesterol transport and oxysterol metabolism in patients with cardiovascular disease.

Year of Publication
2020
Journal
Arteriosclerosis, thrombosis, and vascular biology
Volume
40
Issue
2
Number of Pages
412-425
Date Published
12/2020
ISSN Number
1524-4636
DOI
10.1161/ATVBAHA.119.313633
Alternate Journal
Arterioscler. Thromb. Vasc. Biol.
PMID
31852219
PMCID
PMC7018399
Download citation